Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.

Teen cancers on the rise since 1975

01 Mar 2017

Studies that seek to understand the causes of the spike in incidence of teen cancers is currently needed. Since 1975, there has been a 25-percent overall increase in teen cancers, particularly in testicular and thyroid cancer and non-Hodgkin's lymphoma due to unknown, probably multifactorial reasons.

The study used data from the 2015 Cancer Statistics Review by the SEER programme in order to describe cancer trends among individuals between the ages of 15 and 19. This included trends of histologic cancer groups and sites of cancer.

The rates of change of the annual incidence of teen cancers from 1975 to 2012 were calculated using linear regression analysis.

Such analyses showed that since 1975, incidence rates of cancers in teens increased at least until 2012. Specifically, cumulative incidence at all sites showed an increase of 0.62 percent for females and 0.67 percent for males annually.

In other words, the incidence rates for males and females in 2012, compared to those in 1975, rose by 28 and 26 percent, respectively. Furthermore, of the 4,900 teen cancers diagnosed in the US in 2012, 1,000 cases can be accounted for by this increasing trend.

In females, non-Hodgkin’s lymphoma (2.16 percent), thyroid cancer (2.12 percent) and acute myeloid leukaemia (1.73 percent) showed the greatest annual increase. In males, these were thyroid cancer (1.59 percent), testicular cancer (1.55 percent) and non-Hodgkin’s lymphoma (1.38 percent).

Further studies that explore the reasons behind this rise are needed in addressing this problem.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.